T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective

Meghana Kesireddy; Jairam Krishnamurthy

doi:10.21037/gs-2025-23

T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective

Gland Surg. 2025 Apr 30;14(4):785-790. doi: 10.21037/gs-2025-23. Epub 2025 Apr 25.

Authors

Meghana Kesireddy¹, Jairam Krishnamurthy¹

Affiliation

¹ Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

No abstract available

Keywords: Stage I human epidermal growth factor receptor 2 (HER2)-positive breast cancer; adjuvant therapy; efficacy; toxicity; trastuzumab emtansine.

Publication types

Editorial
Comment